Evidence map›Paper›PMID 35062362›Full record

ArticleViruses2022

Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool Specimens.

Robert A Kozak, Candace Rutherford, Melissa Richard-Greenblatt, N Y Elizabeth Chau, Ana Cabrera, Mia Biondi, Jamie Borlang, Jaqueline Day, Carla Osiowy, Sumathi Ramachandran and 3 more

Open access · goldAbstract readEvaluation Study
In one paragraph

Article in Viruses, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Detection ofmSphere · 2024
    Article
  7. Hepatitis A virus infection.Nature reviews. Disease primers · 2023
    Review
  8. Article
  9. Hepatitis A: Viral Structure, Classification, Life Cycle, Clinical Symptoms, Diagnosis Error, and Vaccination.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2023
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Robert A KozakSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
Candace RutherfordSt. Joseph's Healthcare, Hamilton, ON L8N 4A6, Canada.
Melissa Richard-GreenblattSt. Joseph's Healthcare, Hamilton, ON L8N 4A6, Canada.ORCID 0000-0001-6717-8856
N Y Elizabeth ChauSunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
Ana CabreraPathology and Laboratory Medicine, London Health Sciences Centre, London, ON N6A 5W9, Canada.
Mia BiondiToronto Centre for Liver Disease, University Health Network, Toronto, ON M6H 3M1, Canada.ORCID 0000-0002-1409-9908
Jamie BorlangNational Microbiology Laboratory, Winnipeg, MB R3E 3PG, Canada.
Jaqueline DayNational Microbiology Laboratory, Winnipeg, MB R3E 3PG, Canada.
Carla OsiowyNational Microbiology Laboratory, Winnipeg, MB R3E 3PG, Canada.ORCID 0000-0002-5429-7220
Sumathi RamachandranDivision of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.ORCID 0000-0001-6359-5003
Nancy MayerPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Laurel GlaserPerelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Marek SmiejaSt. Joseph's Healthcare, Hamilton, ON L8N 4A6, Canada.
St. Joseph’s Healthcare Hamilton · CASunnybrook Health Science Centre · CAUniversity of Pennsylvania · USCenters for Disease Control and Prevention · USLondon Health Sciences Centre · CAUniversity Health Network · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis A virus (HAV) is an emerging public health concern and there is an urgent need for ways to rapidly identify cases so that outbreaks can be managed effectively. Conventional testing for HAV relies on anti-HAV IgM seropositivity. However, studies estimate that 10-30% of patients may not be diagnosed by serology. Molecular assays that can directly detect viral nucleic acids have the potential to improve diagnosis, which is key to prevent the spread of infections. In this study, we developed a real-time PCR (RT-PCR) assay to detect HAV RNA for the identification of acute HAV infection. Primers were designed to target the conserved 5'-untranslated region (5'-UTR) of HAV, and the assay was optimized on both the Qiagen Rotor-Gene and the BD MAX. We successfully detected HAV from patient serum and stool samples with moderate differences in sensitivity and specificity depending on the platform used. Our results highlight the clinical utility of using a molecular assay to detect HAV from various specimen types that can be implemented in hospitals to assist with diagnostics, treatment and prevention.

Indexed as

Disease OutbreaksDNA PrimersFecesGenotypeHepatitis AHepatitis A virusHumansLimit of DetectionMolecular Diagnostic TechniquesPhylogenyRNA, ViralSensitivity and SpecificitySerumDNA PrimersRNA, Viralclinical diagnosticsreal-time PCRviral hepatitis

Identifiers

PMID35062362
PMCPMC8777614
OpenAlexW4206649778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.